Skip to main content Help with accessibility Skip to main navigation

Guidelines

Transition of Commissioning Policies

On 1st July 2022 NHS Cheshire and Merseyside Integrated Care Board (ICB) became the new statutory body responsible for ensuring health care services are available to meet the reasonable needs of the people of Cheshire & Merseyside.

Until such time as a single suite of commissioning policies can be developed and adopted, NHS Cheshire and Merseyside will continue to adopt and operate the CCG policies it has inherited at Place/borough level, which means that there will be no immediate change in commissioning policy for local people resident in those Places/boroughs from what was in place prior to 1st July 2022.

NHS Cheshire and Merseyside Commissioning Policies

 

Documents

Date Added: 28 - Sep - 2022

The Pan Mersey Area Prescribing Committee recommends the use of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ixekizumab in the management of ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (NRAxSpA) in accordance with NICE TA383, NICE TA407, NICE TA497, NICE TA718 and NICE TA719..

Prescribing pathway

Body System:
Date Added: 26 - Jun - 2019
Body System:
Date Added: 26 - Jun - 2019
Body System:
Date Added: 28 - Jul - 2022

 

NHS Cheshire and Merseyside PENDING APPROVAL

Body System: